ÂÜÀòÂÒÂ×

Yongzhong (Andrew) Wu has a strong background in research and process chemistry, with experience in both academic and industry settings. Yongzhong (Andrew) currently holds the role of Executive Director and Head of Process Chemistry, CMC at Synnovation Therapeutics since March 2022. Previously, they worked as the Senior Director of Process Chemistry at Prelude Therapeutics from August 2021 to March 2022.

Prior to their industry roles, Andrew held various positions at Incyte, starting as a Senior Research Investigator from January 2008 to February 2010. Yongzhong (Andrew) then progressed to become a Principal Investigator from February 2010 to August 2012, followed by a Senior Principal Investigator from August 2012 to February 2017. Yongzhong (Andrew) achieved the position of Senior Principal Investigator II from February 2017 to August 2019 and concluded their tenure at Incyte as a Research Fellow from August 2019 to August 2021.

Before their industry experience, Andrew gained valuable research experience as a Postdoctoral Research Associate at the University of Pennsylvania from May 2005 to December 2007.

Overall, Andrew Wu has demonstrated their expertise in process chemistry and research through their progressively advancing roles in both academic and industry organizations.

Yongzhong (Andrew) Wu completed their Doctor of Philosophy (PhD) degree in Organic Chemistry from Temple University between the years 2000 and 2005.